David Thomas

Vice President, Industry Research at Biotechnology Innovation Organization (BIO)

Vice President of Industry Research at BIO covering investment, R&D and alliance deal trends as well as regulatory statistics that impact policy initiatives in Washington. Prior to joining BIO, David spent over a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. David is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.

Alle sessies door David Thomas

Educational Panel

di, 12 feb 2019 9 a.m. - 10 a.m.
Shubert Complex